FDA Strengthens Global Clinical Trial Oversight on GCP

The U.S. Food and Drug Administration (FDA) is strengthening its oversight of global clinical research, placing greater emphasis on Good Clinical Practice (GCP), inspection access, human subject protection, informed consent, and the reliability of foreign clinical data used in U.S. regulatory decisions.

The agency emphasized that GCP is the ethical and scientific foundation for clinical investigations submitted to the FDA. It is intended to ensure that clinical trial data and reported results are credible and accurate while protecting the rights, safety, and well-being of trial participants.

Why Foreign Clinical Data Draw Greater Scrutiny

The globalization of clinical research has brought benefits to medical development but has also created challenges for regulatory oversight and data integrity.

The FDA highlighted concerns about multinational trials with few or no U.S. participants. Such studies may be less easily generalized to the American population the products are intended to treat, while also reducing opportunities for U.S. patients to participate in trials of innovative or potentially breakthrough medical products.

The agency also pointed to challenges in inspecting foreign clinical trial sites. Foreign inspections can be more difficult and costly than domestic inspections, including challenges associated with unannounced inspections. In some cases, FDA inspectors have been denied access or asked to accept conditions that would restrict the scope or conduct of an inspection.

FDA’s Expanded Oversight and Inspection Strategy

For the FDA, the central issue is whether clinical evidence can be reliably validated.

The agency said regulatory decisions involving drugs, biologics, and medical devices depend on credible evidence. This requires appropriate human subject protection, independent ethical review, informed consent, and the ability to inspect clinical trial sites and audit records. The standard applies regardless of where a study is conducted.

If the FDA cannot validate that submitted data were collected in accordance with GCP, including when its ability to inspect sites is constrained or denied, the agency may refuse to accept those data in support of a marketing application.

The FDA also said falsified, duplicated, or otherwise invalid data can be excluded from consideration. If the remaining evidence is insufficient to support authorization, the agency has the authority to deny, withhold, or rescind marketing authorization.

FDA Expands Foreign BIMO Inspections

The FDA is adding resources for foreign Bioresearch Monitoring (BIMO) inspections to strengthen oversight of clinical trial sites outside the United States. The expanded effort will include more inspections of Phase 1 and early-stage trials, as well as broader inspection assignments covering additional trials conducted at the same facility.

The agency also plans to update its risk-based criteria for selecting sites for inspection, with the aim of better reflecting compliance risks associated with clinical trials conducted in specific countries or regions.

The move is particularly relevant because the FDA has highlighted the challenges of conducting foreign inspections, including situations where the agency has been denied access to sites or asked to accept conditions that could restrict the scope or conduct of an inspection.

Focus on Non-IND/IDE and Early-Phase Foreign Trials

Foreign clinical studies conducted outside an Investigational New Drug (IND) or Investigational Device Exemption (IDE) framework are another priority area.

Such studies may be accepted in support of a U.S. marketing application when they comply with GCP, including review and approval by an independent ethics committee and informed consent from all participants. However, the FDA is increasing scrutiny of whether foreign data are reliable, inspectable, and ethically derived.

The agency is particularly concerned about Early Feasibility Studies and Phase 1 studies in jurisdictions where geopolitical conditions may make informed consent difficult to ensure or where documented human-rights concerns could increase the risk that consent was not freely and voluntarily given.

FDA audits have identified fabricated participants, falsified health conditions, falsified laboratory results, and concealed adverse events, underscoring the importance of data integrity across clinical development.

The FDA also plans to increase transparency around inspection findings involving foreign clinical trial sites. Where concerns related to human subject protection or data integrity are identified, the agency intends to make more information publicly available, as appropriate.

Strategic Implications for Sponsors

The FDA is encouraging sponsors to address the provenance and regulatory status of foreign clinical data earlier in development. The agency plans to discuss these issues through pre-IND meetings, Type B meetings, and Q-Submissions for medical devices before formal application review.

For sponsors, the message is that geography does not change the evidentiary standard.

The FDA said its approach is not protectionism or a judgment about the scientific capabilities of any particular country. Foreign institutions can generate high-quality clinical data, and the FDA continues to rely on such evidence.

Instead, sponsors are expected to ensure from the beginning that clinical programs can demonstrate GCP compliance, appropriate human subject protection, informed consent, data integrity, and meaningful FDA access to relevant sites and records.

Clinical Significance

The FDA’s renewed focus could make inspection access and data integrity increasingly important considerations when sponsors design global development programs.

For companies conducting clinical trials overseas, the regulatory strategy may need to account for the ability to demonstrate that data are reliable, ethically derived, and capable of FDA validation from the outset.

The agency’s message is straightforward: unreliable or unethical data cannot serve as evidence for a U.S. regulatory decision. Sponsors developing products for the U.S. market should therefore consider GCP compliance, human subject protection, informed consent, data integrity, and FDA inspection access as core elements of clinical development rather than issues to be addressed late in the regulatory process.

Reference

Good Clinical Practices Are Not Optional: The FDA’s Commitment to Human Subject Protections and Gold Standard Science in an Era of Global Clinical Research | FDA